Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 145

1.

Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC.

Samakoglu S, Deevi DS, Li H, Wang S, Murphy M, Bao C, Bassi R, Prewett M, Tonra JR.

Cancer Genomics Proteomics. 2012 Mar-Apr;9(2):77-92.

PMID:
22399498
[PubMed - indexed for MEDLINE]
2.

Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.

Higgins B, Kolinsky K, Smith M, Beck G, Rashed M, Adames V, Linn M, Wheeldon E, Gand L, Birnboeck H, Hoffmann G.

Anticancer Drugs. 2004 Jun;15(5):503-12.

PMID:
15166626
[PubMed - indexed for MEDLINE]
3.

Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.

Steiner P, Joynes C, Bassi R, Wang S, Tonra JR, Hadari YR, Hicklin DJ.

Clin Cancer Res. 2007 Mar 1;13(5):1540-51.

PMID:
17332300
[PubMed - indexed for MEDLINE]
Free Article
4.

The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.

Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK, Bunn PA Jr.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805.

PMID:
15701870
[PubMed - indexed for MEDLINE]
Free Article
5.

The mechanism involved in the loss of PTEN expression in NSCLC tumor cells.

Li G, Zhao J, Peng X, Liang J, Deng X, Chen Y.

Biochem Biophys Res Commun. 2012 Feb 17;418(3):547-52. doi: 10.1016/j.bbrc.2012.01.065. Epub 2012 Jan 21.

PMID:
22290228
[PubMed - indexed for MEDLINE]
6.

Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.

Freeman DJ, Bush T, Ogbagabriel S, Belmontes B, Juan T, Plewa C, Van G, Johnson C, Radinsky R.

Mol Cancer Ther. 2009 Jun;8(6):1536-46. doi: 10.1158/1535-7163.MCT-08-0978. Epub 2009 Jun 9.

PMID:
19509246
[PubMed - indexed for MEDLINE]
Free Article
7.

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J.

Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138.

PMID:
18927285
[PubMed - indexed for MEDLINE]
Free Article
8.

An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.

de Fraipont F, Levallet G, Creveuil C, Bergot E, Beau-Faller M, Mounawar M, Richard N, Antoine M, Rouquette I, Favrot MC, Debieuvre D, Braun D, Westeel V, Quoix E, Brambilla E, Hainaut P, Moro-Sibilot D, Morin F, Milleron B, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique.

Clin Cancer Res. 2012 May 15;18(10):2976-86. doi: 10.1158/1078-0432.CCR-11-2797. Epub 2012 Mar 20.

PMID:
22434665
[PubMed - indexed for MEDLINE]
Free Article
9.

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.

Cavazzoni A, Alfieri RR, Cretella D, Saccani F, Ampollini L, Galetti M, Quaini F, Graiani G, Madeddu D, Mozzoni P, Galvani E, La Monica S, Bonelli M, Fumarola C, Mutti A, Carbognani P, Tiseo M, Barocelli E, Petronini PG, Ardizzoni A.

Mol Cancer. 2012 Dec 12;11:91. doi: 10.1186/1476-4598-11-91.

PMID:
23234355
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.

Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M, Scagliotti GV.

Ann Oncol. 2006 Dec;17(12):1818-25. Epub 2006 Sep 15.

PMID:
16980606
[PubMed - indexed for MEDLINE]
Free Article
11.

Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response.

Judde JG, Rebucci M, Vogt N, de Cremoux P, Livartowski A, Chapelier A, Tran-Perennou C, Boye K, Defrance R, Poupon MF, Bras-Gonçalves RA.

Int J Cancer. 2007 Apr 1;120(7):1579-90.

PMID:
17205515
[PubMed - indexed for MEDLINE]
12.

Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.

Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA Jr.

Clin Cancer Res. 2006 Dec 1;12(23):7117-25.

PMID:
17145836
[PubMed - indexed for MEDLINE]
Free Article
13.

Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.

Denlinger CE, Rundall BK, Keller MD, Jones DR.

Ann Thorac Surg. 2004 Oct;78(4):1207-14; discussion 1207-14.

PMID:
15464472
[PubMed - indexed for MEDLINE]
14.

First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.

Salazar F, Molina MA, Sanchez-Ronco M, Moran T, Ramirez JL, Sanchez JM, Stahel R, Garrido P, Cobo M, Isla D, Bertran-Alamillo J, Massuti B, Cardenal F, Manegold C, Lianes P, Trigo JM, Sanchez JJ, Taron M, Rosell R.

Lung Cancer. 2011 Apr;72(1):84-91. doi: 10.1016/j.lungcan.2010.07.008. Epub 2010 Aug 11.

PMID:
20705357
[PubMed - indexed for MEDLINE]
15.

The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1.

Kim MK, Jeon YK, Woo JK, Choi Y, Choi DH, Kim YH, Kim CW.

Mol Cancer. 2011 Aug 16;10:98. doi: 10.1186/1476-4598-10-98.

PMID:
21843371
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).

Cappuzzo F, Ligorio C, Toschi L, Rossi E, Trisolini R, Paioli D, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Hirsch FR, Crino L, Varella-Garcia M.

J Thorac Oncol. 2007 May;2(5):423-9. Erratum in: J Thorac Oncol. 2007 Jul;2(7):676. Ligorio, Claudio [corrected to Ligorio, Claudia].

PMID:
17473658
[PubMed - indexed for MEDLINE]
17.

Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.

Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2069-77. doi: 10.1007/s00432-012-1291-2. Epub 2012 Jul 22.

PMID:
22821179
[PubMed - indexed for MEDLINE]
18.

EGFR-directed monoclonal antibodies in non-small cell lung cancer.

Pirker R.

Target Oncol. 2013 Mar;8(1):47-53. doi: 10.1007/s11523-012-0244-7. Epub 2013 Jan 9. Review.

PMID:
23300028
[PubMed - indexed for MEDLINE]
19.

14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group.

Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de Las Peñas R, Sanchez JM, Moran T, Camps C, Massuti B, Sanchez JJ, Salazar F, Catot S; Spanish Lung Cancer Group.

J Clin Oncol. 2005 Dec 20;23(36):9105-12.

PMID:
16361617
[PubMed - indexed for MEDLINE]
Free Article
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk